Ellagic acid ameliorates neuroinflammation and demyelination in experimental autoimmune encephalomyelitis: Involvement of NLRP3 and pyroptosis

Kiasalari, Zahra; Afshin‐Majd, Siamak; Baluchnejadmojarad, Tourandokht; Azadi-Ahmadabadi, Ensie; Esmaeil-Jamaat, Elham; Fahanik-Babaei, Javad; Fakour, Marzieh; Fereidouni, Farzane; Ghasemi-Tarie, Reihaneh; Jalalzade-Ogvar, Shahram; Khodashenas, Vahid; Sanaierad, Ashkan; Zahedi, Elham; Roghani, Mehrdad

doi:10.1016/j.jchemneu.2020.101891

Cited by 24 publications

(14 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, a clear reduction of the activation of astrocytes and glial cells (quantified as changes in the density of Iba1 and GFAP stainings in the spinal cord of EAE mice, respectively) emerged in the PEm-treated EAE mice, again predictive of a slowing-down of the disease progression [40][41][42]. We propose that the amelioration of these signs provides a cellular rationale to support the use of the PEm formulation as dietary supplementation during MS. As already introduced, our observations differ by a quantitative point of view from other recent results in the literature [30][31][32]. Differences in the formulation, in the posology (in those works, the nutraceutics were administered with a prophylactic protocol, starting from mice immunization) and in the experimental approach might account for the discrepancy: future studies will be dedicated to evaluating these aspects.…”

Section: Discussioncontrasting

confidence: 83%

“…The authors observed a positive trend in "in vivo" (i.e., loss of weight and clinical score) and in "in vitro" (cytokine production and histopathological staining) parameters in the treated EAE mice. The beneficial effect of EA was also confirmed in the cuprizone-treated mice, which is a model of demyelinating disorder [32,33]. In a whole, these results were promising but typified by a huge variability depending on the formulation, on the timing of the treatment and on the route of administration that in some cases was invasive (gavage, i.p.)…”

Section: Introductionmentioning

confidence: 83%

“…The extract ameliorated the clinical score, reduced the release of the cytokine IL17 in draining CD4 + T cells purified from the popliteal lympho-node and diminished spinal-cord inflammatory infiltrates [31]. Finally, very recently, Kiasalari and colleagues (2021) [32] administered orally (via gavage) EAE mice with EA (50-10 mg/kg/day) emulsified in Cremophor. The authors observed a positive trend in "in vivo" (i.e., loss of weight and clinical score) and in "in vitro" (cytokine production and histopathological staining) parameters in the treated EAE mice.…”

Section: Introductionmentioning

confidence: 98%

See 2 more Smart Citations

Healthy Properties of a New Formulation of Pomegranate-Peel Extract in Mice Suffering from Experimental Autoimmune Encephalomyelitis

et al. 2022

View full text Add to dashboard Cite

A new formulation of a pomegranate-peel extract (PEm) obtained by PUAE (Pulsed Ultrasound-Assisted Extraction) and titrated in both ellagic acid (EA) and punicalagin is proposed, characterized and then analyzed for potential health properties in mice suffering from the experimental autoimmune encephalomyelitis (EAE). PEm effects were compared to those elicited by a formulation containing EA (EAm). Control and EAE mice were chronically administered EAm and Pem dissolved in the drinking water, starting from the day 10 post-immunization (d.p.i.), with a “therapeutic” protocol to deliver daily 50 mg/kg of EA. Treated EAE mice did not limit their daily access to the beverage, nor did they show changes in body weight, but they displayed a significant amelioration of “in vivo” clinical symptoms. “Ex vivo” histochemical analysis showed that spinal-cord demyelination and inflammation in PEm and EAm-treated EAE mice at 23 ± 1 d.p.i. were comparable to those in the untreated EAE animals, while microglia activation (measured as Ionized Calcium Binding Adaptor 1, Iba1 staining) and astrocytosis (quantified as glial fibrillar acid protein, GFAP immunopositivity) significantly recovered, particularly in the gray matter. EAm and PEm displayed comparable efficiencies in controlling the spinal pathological cellular hallmarks in EAE mice, and this would support their delivery as dietary supplementation in patients suffering from multiple sclerosis (MS).

show abstract

Section: Discussioncontrasting

confidence: 83%

Section: Introductionmentioning

confidence: 83%

Section: Introductionmentioning

confidence: 98%

See 1 more Smart Citation

Healthy Properties of a New Formulation of Pomegranate-Peel Extract in Mice Suffering from Experimental Autoimmune Encephalomyelitis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The therapeutic dose range for EA is 0.1–300 mg/kg, and it can be orally and intraperitoneally administered ( Baradaran Rahimi et al, 2020 ). In the animal model of EAE, EA reduced inflammation, and blocked myelin loss and axonal damage ( Kiasalari et al, 2021 ). EA also promotes neuroprotection by decreasing GFAP and Iba1 immunoreactivity ( Busto et al, 2018 ; Kiasalari et al, 2021 ).…”

Section: Nature Productsmentioning

confidence: 99%

“…In the animal model of EAE, EA reduced inflammation, and blocked myelin loss and axonal damage ( Kiasalari et al, 2021 ). EA also promotes neuroprotection by decreasing GFAP and Iba1 immunoreactivity ( Busto et al, 2018 ; Kiasalari et al, 2021 ).…”

Section: Nature Productsmentioning

confidence: 99%

Role of Plant-Derived Natural Compounds in Experimental Autoimmune Encephalomyelitis: A Review of the Treatment Potential and Development Strategy

et al. 2021

View full text Add to dashboard Cite

Multiple sclerosis (MS) is an autoimmune disease of the central nervous system that is mainly mediated by pathological T-cells. Experimental autoimmune encephalomyelitis (EAE) is a well-known animal model of MS that is used to study the underlying mechanism and offers a theoretical basis for developing a novel therapy for MS. Good therapeutic effects have been observed after the administration of natural compounds and their derivatives as treatments for EAE. However, there has been a severe lag in the research and development of drug mechanisms related to MS. This review examines natural products that have the potential to effectively treat MS. The relevant data were consulted in order to elucidate the regulated mechanisms acting upon EAE by the flavonoids, glycosides, and triterpenoids derived from natural products. In addition, novel technologies such as network pharmacology, molecular docking, and high-throughput screening have been gradually applied in natural product development. The information provided herein can help improve targeting and timeliness for determining the specific mechanisms involved in natural medicine treatment and lay a foundation for further study.

show abstract

Remodeling of the Intra‐Conduit Inflammatory Microenvironment to Improve Peripheral Nerve Regeneration with a Neuromechanical Matching Protein‐Based Conduit

Wang,

Yuan,

Zhang

et al. 2024

Advanced Science

View full text Add to dashboard Cite

Peripheral nerve injury (PNI) remains a challenging area in regenerative medicine. Nerve guide conduit (NGC) transplantation is a common treatment for PNI, but the prognosis of NGC treatment is unsatisfactory due to 1) neuromechanical unmatching and 2) the intra‐conduit inflammatory microenvironment (IME) resulting from Schwann cell pyroptosis and inflammatory‐polarized macrophages. A neuromechanically matched NGC composed of regenerated silk fibroin (RSF) loaded with poly(3,4‐ethylenedioxythiophene): poly(styrene sulfonate) (P:P) and dimethyl fumarate (DMF) are designed, which exhibits a matched elastic modulus (25.1 ± 3.5 MPa) for the peripheral nerve and the highest 80% elongation at break, better than most protein‐based conduits. Moreover, the NGC can gradually regulate the intra‐conduit IME by releasing DMF and monitoring sciatic nerve movements via piezoresistive sensing. The combination of NGC and electrical stimulation modulates the IME to support PNI regeneration by synergistically inhibiting Schwann cell pyroptosis and reducing inflammatory factor release, shifting macrophage polarization from the inflammatory M1 phenotype to the tissue regenerative M2 phenotype and resulting in functional recovery of neurons. In a rat sciatic nerve crush model, NGC promoted remyelination and functional and structural regeneration. Generally, the DMF/RSF/P:P conduit provides a new potential therapeutic approach to promote nerve repair in future clinical treatments.

show abstract

Ellagic acid ameliorates neuroinflammation and demyelination in experimental autoimmune encephalomyelitis: Involvement of NLRP3 and pyroptosis

Cited by 24 publications

References 43 publications

Healthy Properties of a New Formulation of Pomegranate-Peel Extract in Mice Suffering from Experimental Autoimmune Encephalomyelitis

Healthy Properties of a New Formulation of Pomegranate-Peel Extract in Mice Suffering from Experimental Autoimmune Encephalomyelitis

Role of Plant-Derived Natural Compounds in Experimental Autoimmune Encephalomyelitis: A Review of the Treatment Potential and Development Strategy

Remodeling of the Intra‐Conduit Inflammatory Microenvironment to Improve Peripheral Nerve Regeneration with a Neuromechanical Matching Protein‐Based Conduit

Contact Info

Product

Resources

About